Galectin Therapeutics Inc
GALT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133416
In the last 90 days, Galectin Therapeutics Inc insiders filed 0 open-market purchases and 3 sales; 98 institutions reported holding it in 13F filings for Q2 2026, worth $72.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $496.3K in total
- 3
- 13F holdersQ2 2026, 0 vs. previous quarter
- 98
- 13F valueReported value at the end of Q2 2026
- $72.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GALT, Q2 2026
No superinvestor reported holding GALT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Galectin Therapeutics Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 16, 2026 (view filing)5:39 PM ET | Jul 14 | 2 days | Jamil KhurramChief Medical Officer | SSale | −16.3K | $5.13 | −$83.3K | −100.0%0 after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26-29 | 4 days | Shlevin Harold H.Director | SSale | −30.0K | $5.03 | −$150.9K | −82.2%6.50K after | 2 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26-29 | 4 days | Jamil KhurramChief Medical Officer | SSale | −52.0K | $5.04 | −$262.1K | −100.0%0 after | 3 lots10b5-1 |
| Jun 25, 2026 (view filing) | Jun 23 | 2 days | Jamil KhurramChief Medical Officer | SSale | −7.56K | $3.14 | −$23.7K | −100.0%0 after | 10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Jamil KhurramChief Medical Officer | SSale | −568 | $3.10 | −$1.76K | −100.0%0 after | 10b5-1 |
| Feb 9, 2026 (view filing) | Feb 6 | 3 days | Eldred KaryDirector | PPurchase | +300 | $2.70 | +$810 | +0.5%65.7K after | |
| Jan 6, 2026 (view filing) | Jan 2-6 | 4 days | Lewis JoelPresident and CEO | SSale | −84.0K | $3.83 | −$321.4K | −9.2%832.6K after | 3 lots10b5-1 |
| Jan 6, 2026 (view filing) | Jan 2-6 | 4 days | Callicutt Jack WChief Financial Officer | SSale | −60.0K | $3.89 | −$233.5K | −88.7%7.61K after | 3 lots10b5-1 |
| Jan 6, 2026 (view filing) | Jan 2-6 | 4 days | Jamil KhurramChief Medical Officer | SSale | −34.5K | $3.86 | −$133.1K | −100.0%0 after | 2 lots10b5-1 |
| Jan 6, 2026 (view filing) | Jan 5 | 1 day | Jamil KhurramChief Medical Officer | SSale | −25.5K | $3.90 | −$99.4K | −54.3%21.4K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Galectin Therapeutics Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,988,353 | $13.9M | 0.00% | +2,189,116+273.9% | Added |
| Vanguard Capital Management LLC | 2,168,065 | $10.1M | 0.00% | +201,523+10.2% | Added |
| Geode Capital Management, LLC | 1,308,394 | $6.07M | 0.00% | +695,608+113.5% | Added |
| Advisor Group Holdings, Inc. | 1,203,725 | $5.59M | 0.01% | +81,055+7.2% | Added |
| Marshall Wace, LLP | 831,010 | $3.86M | 0.00% | −388,902−31.9% | Reduced |
| Wealthspire Advisors, LLC | 721,788 | $3.35M | 0.02% | 00.0% | Unchanged |
| State Street Corp | 567,779 | $2.63M | 0.00% | +309,347+119.7% | Added |
| Commonwealth Equity Services, LLC | 407,113 | $1.89M | 0.00% | +40,000+10.9% | Added |
| Northern Trust Corp | 386,545 | $1.79M | 0.00% | +256,097+196.3% | Added |
| Vanguard Fiduciary Trust Co | 366,476 | $1.70M | 0.00% | +62,235+20.5% | Added |